Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025
Aclarion (Nasdaq: ACON), a healthcare technology company specializing in chronic low back pain diagnosis through biomarkers and AI algorithms, has announced its participation in the Planet MicroCap Showcase: VEGAS 2025. The presentation is scheduled for April 23, 2025, at 12:30 PM ET, where CEO Brent Ness will discuss the company and its recent value-driving initiatives. In conjunction with the event, the company has released an updated investor presentation available on their investor relations website.
Aclarion (Nasdaq: ACON), un'azienda tecnologica nel settore sanitario specializzata nella diagnosi del dolore cronico alla parte bassa della schiena tramite biomarcatori e algoritmi di intelligenza artificiale, ha annunciato la sua partecipazione al Planet MicroCap Showcase: VEGAS 2025. La presentazione è prevista per il 23 aprile 2025, alle 12:30 ET, durante la quale l'amministratore delegato Brent Ness parlerà dell'azienda e delle sue recenti iniziative volte a creare valore. In concomitanza con l'evento, la società ha pubblicato una versione aggiornata della presentazione per gli investitori, disponibile sul sito dedicato alle relazioni con gli investitori.
Aclarion (Nasdaq: ACON), una empresa tecnológica del sector salud especializada en el diagnóstico del dolor lumbar crónico mediante biomarcadores y algoritmos de inteligencia artificial, ha anunciado su participación en el Planet MicroCap Showcase: VEGAS 2025. La presentación está programada para el 23 de abril de 2025 a las 12:30 PM ET, donde el CEO Brent Ness hablará sobre la compañía y sus recientes iniciativas para generar valor. En paralelo al evento, la empresa ha publicado una presentación actualizada para inversores, disponible en su sitio web de relaciones con inversores.
Aclarion (나스닥: ACON)은 바이오마커와 인공지능 알고리즘을 활용한 만성 요통 진단에 특화된 헬스케어 기술 기업으로, Planet MicroCap Showcase: VEGAS 2025에 참가한다고 발표했습니다. 발표는 2025년 4월 23일 오후 12시 30분(동부시간)에 예정되어 있으며, CEO 브렌트 네스가 회사와 최근 가치 창출 이니셔티브에 대해 설명할 예정입니다. 행사와 함께 회사는 투자자 관계 웹사이트에 최신 투자자 프레젠테이션을 공개했습니다.
Aclarion (Nasdaq : ACON), une entreprise technologique spécialisée dans le diagnostic des douleurs lombaires chroniques grâce aux biomarqueurs et aux algorithmes d'IA, a annoncé sa participation au Planet MicroCap Showcase : VEGAS 2025. La présentation est prévue le 23 avril 2025 à 12h30 ET, où le PDG Brent Ness présentera l’entreprise ainsi que ses récentes initiatives créatrices de valeur. Parallèlement à l'événement, la société a publié une présentation mise à jour pour les investisseurs, disponible sur son site web dédié aux relations investisseurs.
Aclarion (Nasdaq: ACON), ein Unternehmen im Bereich Gesundheitstechnologie, das sich auf die Diagnose chronischer Rückenschmerzen mithilfe von Biomarkern und KI-Algorithmen spezialisiert hat, hat seine Teilnahme am Planet MicroCap Showcase: VEGAS 2025 bekanntgegeben. Die Präsentation ist für den 23. April 2025 um 12:30 Uhr ET geplant, bei der CEO Brent Ness das Unternehmen und seine jüngsten wertsteigernden Initiativen vorstellen wird. Im Zusammenhang mit der Veranstaltung hat das Unternehmen eine aktualisierte Investorenpräsentation auf seiner Investor-Relations-Website veröffentlicht.
- None.
- None.
BROOMFIELD, Colo., April 23, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 12:30 PM ET.
Brent Ness, Chief Executive Officer of Aclarion, will be presenting on the Company and recent value-driving initiatives.
In conjunction with the event, Aclarion has published its updated investor presentation, which can be found on its website at https://investors.aclarion.com/.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contact:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
FAQ
When is Aclarion (ACON) presenting at Planet MicroCap Showcase 2025?
Where can I find Aclarion's (ACON) latest investor presentation?
What technology does Aclarion (ACON) use for chronic low back pain diagnosis?
Who will be presenting for Aclarion (ACON) at the Planet MicroCap Showcase?
